Pharmaceutical Products

Bremelanotide;PT-141
Cas No.:32780-32-8
Molecular Formula:C50H68N14O10
Molecular Weight:1025.2
Purity (HPLC):98.0%min.
Single Impurity (HPLC):1.0%max
Amino Acid Composition:About 10% of theoretical
Peptide Content (N%):80.0% min.
Water Content(Karl Fischer):6.0%max.
Acetate Content (HPIC):15.0%max.
MS(ESI):Consistent
Mass Balance:95.0~105.0%
Appearance:White powder

Description:

Bremelanotide (formerly PT-141) is a compound under drug development by Palatin Technologies as a treatment for female sexual dysfunction, hemorrhagic shock and reperfusion injury.It functions by activating the melanocortin receptors MC1R and MC4R, to modulate inflammation and limiting ischemia.It was originally tested for intranasal administration in treating female sexual dysfunction but this application was temporarily discontinued in 2008 after concerns were raised over adverse side effects of increased blood pressure.As of March 2012, Palatin is conducting a human Phase 2B study using a new subcutaneous drug delivery system that appears to have little effect on blood pressure.

When PT141 was administered to male animals that suffered from erectile dysfunction but otherwise exhibited normal health, erectile activity would improve. The increase in erectile activity was directly linked to a dependence on the application of PT141 and the given levels of the application in the given test subject. While these results are initial and somewhat limiting in nature, they imply that PT141 may have potential in therapeutic treatment of erectile disorders in the future.